A 58-year-old man with a 3-year history of dilated cardiomyopathy (ejection fraction 28%) presents with progressive dyspnea on exertion, orthopnea, and peripheral edema. He is currently on lisinopril 10 mg daily and furosemide 40 mg daily. His blood pressure is 110/70 mmHg, heart rate 92/min, and JVP is elevated. Echocardiography confirms LVEF 28% with no significant valvular disease. His serum creatinine is 1.2 mg/dL and potassium is 4.1 mEq/L. Which of the following drugs should be added next to reduce mortality in this patient?

Explanation

## Clinical Context This patient has symptomatic heart failure with reduced ejection fraction (HFrEF, LVEF ≤35%) already on an ACE inhibitor (lisinopril) and diuretic. The next evidence-based step is to add a **beta-blocker**, specifically a cardioselective agent with vasodilatory properties. ## Why Carvedilol? **Key Point:** Beta-blockers are foundational mortality-reducing agents in HFrEF and are recommended as first-line therapy alongside ACE inhibitors/ARBs. **High-Yield:** Carvedilol is a non-selective beta-blocker with alpha-1 blocking properties, providing additional vasodilation. It has proven mortality benefit in HFrEF (COPERNICUS, CIBIS trials). **Clinical Pearl:** In HFrEF, beta-blockers must be titrated slowly ("start low, go slow") to avoid acute decompensation. Carvedilol is preferred over metoprolol succinate in many guidelines due to superior mortality reduction in some populations. ## Mechanism of Benefit in HFrEF 1. Reduces sympathetic overstimulation (counteracts compensatory tachycardia) 2. Decreases myocardial oxygen demand 3. Prevents arrhythmias 4. Reduces ventricular remodeling 5. Improves diastolic function ## Guideline-Recommended Sequence for HFrEF | Step | Drug Class | Indication | Evidence | |------|-----------|-----------|----------| | 1 | ACE-I / ARB / ARNI | All HFrEF | Mortality reduction | | 2 | Beta-blocker (Carvedilol, Bisoprolol, Metoprolol succinate) | All HFrEF | Mortality reduction | | 3 | MRA (Spironolactone / Eplerenone) | LVEF ≤35% | Mortality reduction | | 4 | SGLT2i (Dapagliflozin, Empagliflozin) | All HFrEF | Mortality & HF hospitalization reduction | | 5 | Ivabradine | LVEF ≤35%, HR ≥70 | Reduces HF hospitalization | **Mnemonic:** **ABCDE of HFrEF** — **A**CE-I/**ARB**, **B**eta-blocker, **C**aldwell (MRA), **D**apagliflozin (SGLT2i), **E**plerenone (MRA alternative). ## Why Not the Others? - **Amlodipine:** A dihydropyridine calcium channel blocker without mortality benefit in HFrEF; may worsen fluid retention. - **Hydralazine + isosorbide dinitrate:** Reserved for patients intolerant of ACE-I/ARB or as adjunctive therapy; not first-line after ACE-I. - **Verapamil:** A non-dihydropyridine CCB with negative inotropic effects; contraindicated in systolic HF due to risk of decompensation. [cite:Harrison 21e Ch 297]